A novel tripodal ligand (H 3 L 1 ) has been prepared by condensation of tris(2-aminoethyl)amine with 2,6-diformyl-4-methylphenol in MeOH. The compound has three equivalent side-arms, each containing four possible donor groups, an imine N atom, a phenol O atom and two O-donors from an acetal group. The crystal structure showed the arms to be arranged such that a non-crystallographic three-fold axis passes through the bridgehead N atom. Reaction of H 3 L 1 with lanthanoid perchlorate salts resulted in the isolation of two series of complexes. With early lanthanoids compounds of stoichiometry [Ln(H 3 L 1 )(H 2 O)][ClO 4 ] 3 were obtained and the compounds with Ln = La and Pr have been structurally characterised. The lanthanoid site in these complexes is ten co-ordinate, with a geometry which can be related to an icosahedron. For later lanthanoids, complexes of stoichiometry [Ln(H 3 L 1 )][ClO 4 ] 3 are found in which the lanthanoid site is nine-co-cordinate, with a tricapped trigonal-prismatic geometry. The complex with Ln = Y has been characterised by diffraction techniques. Mass spectroscopic studies indicated that the acetal functions within H 3 L 1 are stabilised by co-ordination to the lanthanoid metals. Reaction of the complex [La(H 3 L 1 )(H 2 O)][ClO 4 ] 3 with nickel(II) perchlorate led to a novel heterobimetallic complex in which both La and Ni are encapsulated within the tripodal ligand.
No takes yet. Share an insight, caveat, or question.
Archibald et al. (1997) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: